Company announcement – No. 20 / 2020 Zealand Pharma presents positive clinical and health economic outcome data with use of regular human insulin delivered by the V-Go in.

Zealand Pharma A/S (ZEAL.CO) (CVR No. 20045078), a biotechnology company changing lives with innovative peptide-based medicines, today announced financial results for the first quarter of 2020. Establishing U.S. commercial operations was accelerated by acquiring substantially all of the business assets of Valeritas Holdings, Inc., including the marketed V-Go® wearable insulin delivery device, and transferring 110 employees as well as supporting systems, processes and the majority of established contracts, in a cash transaction of USD 23.0 million on April 2.

Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcements No. 05/2020 from March 20, 2020, Zealand announced an increase in share capital relating to the exercise of employee warrants, and in No. 09/2020 from March 26, 2020 and No. 11/2020 from March 31, 2020, Zealand announced an increase in share capital relating to the completion of a private placement and directed issue of new shares.

Company Announcement – No. 28 / 2020 Zealand Pharma announces FDA acceptance of New Drug Application for the dasiglucagon HypoPal® rescue pen for treatment of severe.

In reference to Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78) company announcement 09/2020 published March 26, 2020, regarding a private placement and directed issue of 741,816 new shares of the company (the "New Ordinary Shares"), Zealand Pharma A/S ("Zealand") announces that it has today increased its share capital by DKK 741,816, divided into 741,816 New Ordinary Shares with a nominal value of DKK 1 each. Following the registration of the New Ordinary Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 36,887,952 divided into 36,887,952 shares with a nominal value of DKK 1 each.

Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20045078) has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file.

Zealand Pharma A/S (ZEAL.CO) (CVR-no. 20045078), announced that it will host a conference call on May 14, 2020 at 4 pm CEST (10 am EDT) following the announcement of results for the first quarter of 2020. Presenting during the call will be President and Chief Executive Officer Emmanuel Dulac, Senior Vice President and Chief Financial Officer Matt Dallas, and Executive Vice President and Chief Medical Officer Adam Steensberg.

Press Release – No. 04 / 2020 Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

ZEAL earnings call for the period ending March 31, 2020.

Zealand Pharma (ZEAL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yesterday, Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20045078), held its Annual General Meeting of 2020 at Zealand Pharma A/S, Sydmarken 11, DK-2860 Søborg, Denmark. At the meeting, all proposals presented to the General Meeting were adopted. The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and Zealand's audited Annual Report for 2019 was approved.

Zealand Pharma A/S (“Zealand” or the “Company”) (ZEAL.CO) (CVR-no. 20045078), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that the acquisition of substantially all assets of Valeritas Holdings, Inc. (VLRX) has been completed for the cash purchase price of $23 million and the assumption of certain liabilities related to the ongoing business, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with Valeritas and following approval by the U.S. Bankruptcy Court for the District of Delaware on March 20, 2020. “We are thrilled to welcome more U.S. employees to the Zealand team, along with the opportunity to offer the V-Go® wearable insulin delivery device to help people manage their diabetes,” commented Emmanuel Dulac, President and Chief Executive Officer of Zealand Pharma.

Zealand Pharma A/S (ZEAL.CO) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines, today announced that its Articles of Association have been amended to reflect the recent grant of warrants to the Company’s Executive Management and Corporate Management, as announced in Company Announcement no. 21 / 2020 on April 15, 2020. The amendments to Zealand’s Articles of Association entailed by the share capital increase have been registered today with the Danish Business Authority.

Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78), announces the implementation of an updated long-term incentive program (the “LTIP”) for Zealand’s Executive Management and Corporate Management in accordance with Zealand's Remuneration policy and Overall guidelines for incentive pay, as adopted at the annual general meeting held on April 2, 2020. In accordance with the LTIP, Zealand has granted 21,602 restricted stock units (RSUs) to Executive and Corporate Management.

Company announcement – No. 13 / 2020 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely.

Company announcement – No. 14 / 2020 Zealand Pharma provides business update related to current COVID-19 situation Strong progress in discovery and clinical pipeline, with.

Zealand Pharma A/S (ZEAL.CO) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, announced the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 19/2020 from April 15, 2020, Zealand announced an increase in share capital relating to the exercise of employee warrants.

Company announcement – No. 17 / 2020 Zealand Pharma major shareholder announcement: Wellington Management Group LLP Copenhagen, April 6, 2020 – Zealand Pharma A/S (“Zealand”).

Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 90,871 divided into 90,871 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand's employee warrant programs.